Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a clinical study titled ‘A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Mylotarg®’ to evaluate the safety and effectiveness of Mylotarg in treating acute myeloid leukemia (AML). The study aims to monitor the safety of Mylotarg, focusing on adverse reactions and disease progression in newly diagnosed AML patients in Korea.
Mylotarg, the intervention being tested, is a medication designed to treat AML by targeting CD33-positive leukemia cells. The study seeks to determine its safety profile and effectiveness in routine clinical settings.
The study is observational, using a cohort model with a prospective time perspective. It is non-interventional, meaning that patient treatment and monitoring are part of routine practice, without additional experimental procedures.
The study began on December 5, 2023, and is currently recruiting participants. The last update was submitted on June 27, 2025. These dates are crucial for tracking the study’s progress and ensuring up-to-date information for stakeholders.
This study could influence Pfizer’s stock performance by providing insights into Mylotarg’s market potential and safety profile. Positive results might boost investor confidence, while any safety concerns could affect market sentiment. Competitors in the AML treatment space will also be watching closely.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.